Pharsight

Drug Patents Expiring in 2028

1. Abilify Mycite Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9119554 OTSUKA Pharma-informatics system
Dec, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-150) Dec 05, 2017
New Indication(I-746) Jul 27, 2020

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

ABILIFY MYCITE KIT family patents

Family Patents

2. Acuvail patents expiration

ACUVAIL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9192571 ABBVIE Ketorolac tromethamine compositions for treating or preventing ocular pain
Mar, 2028

(3 years from now)

US8512717 ABBVIE Compositions for delivery of therapeutics into the eyes and methods for making and using same
Mar, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 22, 2012

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 22 July, 2009

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACUVAIL before it's drug patent expiration?
More Information on Dosage

ACUVAIL family patents

Family Patents

3. Acuvue Theravision With Ketotifen patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9474746 JOHNSON JOHNSON VISN Methods for stabilizing oxidatively unstable compositions
Mar, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 25, 2025

Drugs and Companies using KETOTIFEN FUMARATE ingredient

Market Authorisation Date: 25 February, 2022

Treatment: NA

Dosage: DRUG-ELUTING CONTACT LENS;OPHTHALMIC

More Information on Dosage

ACUVUE THERAVISION WITH KETOTIFEN family patents

Family Patents

4. Addyi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7151103 SPROUT PHARMS Method of treating female hypoactive sexual desire disorder with flibanserin
May, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 18, 2020

Drugs and Companies using FLIBANSERIN ingredient

NCE-1 date: 19 August, 2019

Market Authorisation Date: 18 August, 2015

Treatment: Use of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat hypoactive sexual desire disorder (hsdd)

Dosage: TABLET;ORAL

More Information on Dosage

ADDYI family patents

Family Patents

5. Afinitor patents expiration

AFINITOR's oppositions filed in EPO
AFINITOR Litigations
Can you believe AFINITOR received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9006224 NOVARTIS Neuroendocrine tumor treatment
Jul, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-724) Feb 26, 2019
Orphan Drug Exclusivity(ODE-108) Feb 26, 2023
Orphan Drug Exclusivity(ODE-24) Apr 26, 2019
Orphan Drug Exclusivity(ODE-11) May 05, 2018
New Chemical Entity Exclusivity(NCE) Mar 30, 2014
New Indication(I-630) Oct 29, 2013
New Indication(I-655) Jul 20, 2015
New Indication(I-650) Apr 26, 2015
Orphan Drug Exclusivity(ODE) Apr 26, 2019
Pediatric Exclusivity(PED) Oct 26, 2015
New Indication(I-638) May 05, 2014

Drugs and Companies using EVEROLIMUS ingredient

NCE-1 date: 26 October, 2014

Market Authorisation Date: 09 July, 2010

Treatment: Treatment of patients with progressive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic

Dosage: TABLET;ORAL

How can I launch a generic of AFINITOR before it's drug patent expiration?
More Information on Dosage

AFINITOR family patents

Family Patents

6. Afrezza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8729019 MANNKIND Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
Dec, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 27, 2017

Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient

Market Authorisation Date: 27 June, 2014

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

AFREZZA family patents

Family Patents

7. Airduo Digihaler patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8651103 TEVA PHARM Dry powder inhalation apparatus
Mar, 2028

(3 years from now)

US8651103

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Sep, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-61) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025
New Product(NP) Jan 27, 2020

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

AIRDUO DIGIHALER family patents

Family Patents

8. Airduo Respiclick patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8651103 TEVA PHARM Dry powder inhalation apparatus
Mar, 2028

(3 years from now)

US8651103

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Sep, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-61) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025
New Product(NP) Jan 27, 2020

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 12 July, 2019

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

AIRDUO RESPICLICK family patents

Family Patents

9. Alvesco patents expiration

ALVESCO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8371292 COVIS Use of ciclesonide for the treatment of respiratory diseases
Feb, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 20, 2011
M(M-125) Dec 17, 2015

Drugs and Companies using CICLESONIDE ingredient

NCE-1 date: 20 October, 2010

Market Authorisation Date: 10 January, 2008

Treatment: Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a respiratory disease in a child

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

ALVESCO family patents

Family Patents

10. Ameluz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11540981 BIOFRONTERA Nanoemulsion formulation with improved stability and cell penetration
Feb, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 10, 2019

Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient

Market Authorisation Date: 10 May, 2016

Treatment: NA

Dosage: GEL;TOPICAL

More Information on Dosage

AMELUZ family patents

Family Patents

11. Amvuttra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(4 years from now)

US10806791 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(4 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(4 years from now)

US9370581 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 13, 2027
Orphan Drug Exclusivity(ODE-212) Jun 13, 2029

Drugs and Companies using VUTRISIRAN SODIUM ingredient

NCE-1 date: 13 June, 2026

Market Authorisation Date: 13 June, 2022

Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

AMVUTTRA family patents

Family Patents

12. Angiomax patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7582727 SANDOZ Pharmaceutical formulations of bivalirudin and processes of making the same
Jul, 2028

(4 years from now)

US7598343 SANDOZ Pharmaceutical formulations of bivalirudin and processes of making the same
Jul, 2028

(4 years from now)

Drugs and Companies using BIVALIRUDIN ingredient

Market Authorisation Date: 15 December, 2000

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ANGIOMAX before it's drug patent expiration?
More Information on Dosage

ANGIOMAX family patents

Family Patents

13. Anoro Ellipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8161968 GLAXOSMITHKLINE Medicament dispenser
Feb, 2028

(3 years from now)

US9333310

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Apr, 2028

(3 years from now)

US8113199

(Pediatric)

GLAXOSMITHKLINE Counter for use with a medicament dispenser
Apr, 2028

(4 years from now)

US8161968

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Aug, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 18, 2016
New Chemical Entity Exclusivity(NCE) Dec 18, 2018
M(M-245) Jun 09, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 18 December, 2017

Market Authorisation Date: 18 December, 2013

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ANORO ELLIPTA family patents

Family Patents

14. Aptiom patents expiration

APTIOM's oppositions filed in EPO
Can you believe APTIOM received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9763954 SUMITOMO PHARMA AM Therapeutical uses of eslicarbazepine
Sep, 2028

(4 years from now)

US9566244 SUMITOMO PHARMA AM Pharmaceutical composition comprising licarbazepine acetate
Oct, 2028

(4 years from now)

US10912781 SUMITOMO PHARMA AM Pharmaceutical composition comprising licarbazepine acetate
Oct, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-150) Aug 27, 2018
New Indication(I-715) Aug 27, 2018
New Chemical Entity Exclusivity(NCE) Nov 08, 2018

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

NCE-1 date: 08 November, 2017

Market Authorisation Date: 08 November, 2013

Treatment: Treatment of partial-onset seizures in patients with epilepsy who have been previously treated with oxcarbazepine

Dosage: TABLET;ORAL

How can I launch a generic of APTIOM before it's drug patent expiration?
More Information on Dosage

APTIOM family patents

Family Patents

15. Arcapta Neohaler patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8479730 NOVARTIS Inhaler device
Oct, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 01, 2016

Drugs and Companies using INDACATEROL MALEATE ingredient

NCE-1 date: 02 July, 2015

Market Authorisation Date: 01 July, 2011

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARCAPTA NEOHALER family patents

Family Patents

16. Arikayce Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8226975 INSMED INC Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
Aug, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-214) Sep 28, 2025
Generating Antibiotic Incentives Now(GAIN) Sep 28, 2030

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: NA

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

More Information on Dosage

ARIKAYCE KIT family patents

Family Patents

17. Armonair Digihaler patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8651103 TEVA PHARM Dry powder inhalation apparatus
Mar, 2028

(3 years from now)

US8651103

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Sep, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 09, 2024
New Strength(NS) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025
New Product(NP) Jan 27, 2020

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARMONAIR DIGIHALER family patents

Family Patents

18. Armonair Respiclick patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8651103 TEVA PHARM Dry powder inhalation apparatus
Mar, 2028

(3 years from now)

US8651103

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus
Sep, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 09, 2024
New Strength(NS) Jul 09, 2024
Pediatric Exclusivity(PED) Jan 09, 2025
New Product(NP) Jan 27, 2020

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 08 April, 2022

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARMONAIR RESPICLICK family patents

Family Patents

19. Arnuity Ellipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8161968 GLAXOSMITHKLINE Medicament dispenser
Feb, 2028

(3 years from now)

US9333310

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Apr, 2028

(3 years from now)

US8113199

(Pediatric)

GLAXOSMITHKLINE Counter for use with a medicament dispenser
Apr, 2028

(4 years from now)

US8161968

(Pediatric)

GLAXOSMITHKLINE Medicament dispenser
Aug, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-290) Mar 01, 2026
New Strength(NS) May 17, 2021
New Patient Population(NPP) May 17, 2021
New Product(NP) Aug 20, 2017

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 17 May, 2018

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARNUITY ELLIPTA family patents

Family Patents

20. Astepro patents expiration

ASTEPRO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071073 MYLAN SPECIALITY LP Compositions comprising azelastine and methods of use thereof
Jun, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 15, 2011
New Patient Population(NPP) Aug 30, 2016
M(M-129) Aug 30, 2016

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 October, 2008

Treatment: NA

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of ASTEPRO before it's drug patent expiration?
More Information on Dosage

ASTEPRO family patents

Family Patents

21. Astepro patents expiration

ASTEPRO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071073 MEDA PHARMS Compositions comprising azelastine and methods of use thereof
Jun, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 31, 2012

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 31 August, 2009

Treatment: NA

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of ASTEPRO before it's drug patent expiration?
More Information on Dosage

ASTEPRO family patents

Family Patents

22. Astepro Allergy patents expiration

ASTEPRO ALLERGY Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071073 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof
Jun, 2028

(4 years from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2021

Treatment: NA

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of ASTEPRO ALLERGY before it's drug patent expiration?
More Information on Dosage

ASTEPRO ALLERGY family patents

Family Patents

23. Atelvia patents expiration

ATELVIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7645459 APIL Dosage forms of bisphosphonates
Jan, 2028

(3 years from now)

US7645460 APIL Dosage forms of risedronate
Jan, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Oct 08, 2013

Drugs and Companies using RISEDRONATE SODIUM ingredient

Market Authorisation Date: 08 October, 2010

Treatment: Treatment of osteoporosis in postmenopausal women

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of ATELVIA before it's drug patent expiration?
More Information on Dosage

ATELVIA family patents

Family Patents

24. Auvi-q patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947017 KALEO INC Devices, systems and methods for medicament delivery
Mar, 2028

(3 years from now)

US7749194 KALEO INC Devices, systems, and methods for medicament delivery
Oct, 2028

(4 years from now)

US8231573 KALEO INC Medicament delivery device having an electronic circuit system
Nov, 2028

(4 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 17 November, 2017

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

AUVI-Q family patents

Family Patents

25. Bevyxxa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8557852 PORTOLA PHARMS INC Methods of using crystalline forms of a salt of a factor Xa inhibitor
Sep, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 23, 2022

Drugs and Companies using BETRIXABAN ingredient

NCE-1 date: 23 June, 2021

Market Authorisation Date: 23 June, 2017

Treatment: Prophylaxis of venous thrombosis

Dosage: CAPSULE;ORAL

More Information on Dosage

BEVYXXA family patents

Family Patents

26. Brenzavvy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8802637 THERACOSBIO Benzylbenzene derivatives and methods of use
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8106021 THERACOSBIO Benzylbenzene derivatives and methods of use
Aug, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 20, 2028

Drugs and Companies using BEXAGLIFLOZIN ingredient

NCE-1 date: 20 January, 2027

Market Authorisation Date: 20 January, 2023

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

More Information on Dosage

BRENZAVVY family patents

Family Patents

27. Breo Ellipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8161968 GLAXO GRP LTD Medicament dispenser
Feb, 2028

(3 years from now)

US9333310

(Pediatric)

GLAXO GRP LTD Medicament dispenser
Apr, 2028

(3 years from now)

US8113199

(Pediatric)

GLAXO GRP LTD Counter for use with a medicament dispenser
Apr, 2028

(4 years from now)

US8161968

(Pediatric)

GLAXO GRP LTD Medicament dispenser
Aug, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) May 13, 2026
New Strength(NS) May 13, 2026
Pediatric Exclusivity(PED) Nov 13, 2026
M(M-202) May 15, 2020
New Product(NP) May 10, 2016
New Chemical Entity Exclusivity(NCE) May 10, 2018
New Indication(I-708) Apr 30, 2018

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

NCE-1 date: 13 November, 2025

Market Authorisation Date: 12 May, 2023

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

BREO ELLIPTA family patents

Family Patents

28. Bydureon patents expiration

BYDUREON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8216180 ASTRAZENECA AB Administering apparatus with functional drive element
Jan, 2028

(3 years from now)

US8221786 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8439864 ASTRAZENECA AB Device for administering fluid from a multi-chamber ampoule in incremental steps
Mar, 2028

(3 years from now)

US7851502 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Aug, 2028

(4 years from now)

US8361972

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Sep, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jan 22, 2025
New Patient Population(NPP) Jul 22, 2024
M(M-240) Feb 15, 2022
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
M(M-224) Apr 02, 2021
New Product(NP) Jan 27, 2015

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON family patents

Family Patents

29. Bydureon Bcise patents expiration

BYDUREON BCISE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8361972

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Sep, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025
M(M-240) Feb 15, 2022
New Product(NP) Oct 20, 2020

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON BCISE family patents

Family Patents

30. Bydureon Pen patents expiration

BYDUREON PEN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8216180 ASTRAZENECA AB Administering apparatus with functional drive element
Jan, 2028

(3 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8221786 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US9320853 ASTRAZENECA AB Method for administering a fluid active substance from a multi-chamber ampoule
Mar, 2028

(3 years from now)

US8439864 ASTRAZENECA AB Device for administering fluid from a multi-chamber ampoule in incremental steps
Mar, 2028

(3 years from now)

US8758292

(Pediatric)

ASTRAZENECA AB Administering apparatus with functional drive element
May, 2028

(4 years from now)

US8216180

(Pediatric)

ASTRAZENECA AB Administering apparatus with functional drive element
Jul, 2028

(4 years from now)

US7851502 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Aug, 2028

(4 years from now)

US8361972

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Sep, 2028

(4 years from now)

US8439864

(Pediatric)

ASTRAZENECA AB Device for administering fluid from a multi-chamber ampoule in incremental steps
Sep, 2028

(4 years from now)

US9320853

(Pediatric)

ASTRAZENECA AB Method for administering a fluid active substance from a multi-chamber ampoule
Sep, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jan 22, 2025
New Patient Population(NPP) Jul 22, 2024
M(M-240) Feb 15, 2022
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
M(M-224) Apr 02, 2021
New Product(NP) Jan 27, 2015

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON PEN family patents

Family Patents

31. Canasa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8436051 ABBVIE Mesalamine suppository
Jun, 2028

(4 years from now)

US8217083 ABBVIE Mesalamine suppository
Jun, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-187) Sep 02, 2019

Drugs and Companies using MESALAMINE ingredient

Market Authorisation Date: 05 November, 2004

Treatment: NA

Dosage: SUPPOSITORY;RECTAL

How can I launch a generic of CANASA before it's drug patent expiration?
More Information on Dosage

CANASA family patents

Family Patents

32. Caplyta patents expiration

Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10464938 INTRA-CELLULAR Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof
Mar, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 20, 2024
New Indication(I-882) Dec 17, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: 21 December, 2023

Market Authorisation Date: 22 April, 2022

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

CAPLYTA family patents

Family Patents

33. Caprelsa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8067427 GENZYME CORP Pharmaceutical compositions comprising ZD6474
Aug, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-9) Apr 06, 2018
Orphan Drug Exclusivity(ODE) Apr 06, 2018
New Chemical Entity Exclusivity(NCE) Apr 06, 2016

Drugs and Companies using VANDETANIB ingredient

NCE-1 date: 07 April, 2015

Market Authorisation Date: 06 April, 2011

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

CAPRELSA family patents

Family Patents

34. Carnexiv patents expiration

CARNEXIV's oppositions filed in EPO
CARNEXIV Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9629797 LUNDBECK PHARMS LLC Parenteral carbamazepine formulation
Nov, 2028

(4 years from now)

US9770407 LUNDBECK PHARMS LLC Parenteral carbamazepine formulation
Nov, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Oct 07, 2023
Orphan Drug Exclusivity(ODE-124) Oct 07, 2023

Drugs and Companies using CARBAMAZEPINE ingredient

Market Authorisation Date: 07 October, 2016

Treatment: Replacement therapy for oral carbamazepine in adults with mixed seizure patterns that include partial seizures with complex symptomatology, generalized tonic-clonic seizures, or other partial or gener...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

CARNEXIV family patents

Family Patents

35. Children's Astepro Allergy patents expiration

CHILDREN'S ASTEPRO ALLERGY Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071073 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof
Jun, 2028

(4 years from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2021

Treatment: NA

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of CHILDREN'S ASTEPRO ALLERGY before it's drug patent expiration?
More Information on Dosage

CHILDREN'S ASTEPRO ALLERGY family patents

Family Patents

36. Colcrys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8093298 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Oct, 2028

(4 years from now)

US7964648 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Oct, 2028

(4 years from now)

US8415396 TAKEDA PHARMS USA Colchine compositions and methods
Oct, 2028

(4 years from now)

US8093296 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Oct, 2028

(4 years from now)

US7964647 TAKEDA PHARMS USA Colchicine compositions and methods
Oct, 2028

(4 years from now)

US8415395 TAKEDA PHARMS USA Colchicine compositions and methods
Oct, 2028

(4 years from now)

US8097655 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Oct, 2028

(4 years from now)

US8093297 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Oct, 2028

(4 years from now)

US7981938 TAKEDA PHARMS USA Colchicine compositions and methods
Oct, 2028

(4 years from now)

US7935731 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Dec, 2028

(4 years from now)

US7619004 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Dec, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Jul 29, 2016
New Indication(I-603) Jul 30, 2012

Drugs and Companies using COLCHICINE ingredient

Market Authorisation Date: 29 July, 2009

Treatment: Method of administering colchicine to familial mediterranean fever patients; For the treatment and prophylaxis of gout flares & the treatment of familial mediterranean fever; Method of treating gout f...

Dosage: TABLET;ORAL

How can I launch a generic of COLCRYS before it's drug patent expiration?
More Information on Dosage

COLCRYS family patents

Family Patents

37. Combivent Respimat patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 07, 2014

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

How can I launch a generic of COMBIVENT RESPIMAT before it's drug patent expiration?
More Information on Dosage

COMBIVENT RESPIMAT family patents

Family Patents

38. Cresemba patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603280

(Pediatric)

ASTELLAS Active ingredient containing stabilised solid medicinal forms and methods for the production thereof
Mar, 2028

(3 years from now)

US10206879

(Pediatric)

ASTELLAS Active ingredient containing stabilised solid forms and method for the production thereof
Mar, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-90) Mar 06, 2022
New Chemical Entity Exclusivity(NCE) Mar 06, 2020
Orphan Drug Exclusivity(ODE-305) Mar 06, 2022
Orphan Drug Exclusivity(ODE-458) Dec 08, 2030
New Patient Population(NPP) Dec 08, 2026
Orphan Drug Exclusivity(ODE-454) Dec 08, 2030
ODE*(ODE*) Mar 06, 2022
Pediatric Exclusivity(PED) Jun 08, 2031
Generating Antibiotic Incentives Now(GAIN) Sep 06, 2027
Orphan Drug Exclusivity(ODE) Mar 06, 2022

Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient

NCE-1 date: 08 June, 2030

Market Authorisation Date: 22 November, 2022

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

CRESEMBA family patents

Family Patents

39. Cubicin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8003673 CUBIST PHARMS LLC Daptomycin for the treatment of biofilm and catheter salvage
Sep, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-211) Sep 01, 2020
New Patient Population(NPP) Mar 29, 2020

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 12 September, 2003

Treatment: Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocardi...

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of CUBICIN before it's drug patent expiration?
More Information on Dosage

CUBICIN family patents

Family Patents

40. Dalvance patents expiration

DALVANCE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6900175 ABBVIE Methods of administering dalbavancin for treatment of bacterial infections
May, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 23, 2019
New Patient Population(NPP) Jul 22, 2024
Generating Antibiotic Incentives Now(GAIN) May 23, 2024
New Dosing Schedule(D-154) Jan 20, 2019

Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient

NCE-1 date: 24 May, 2023

Market Authorisation Date: 23 May, 2014

Treatment: Treatment of acute bacterial skin and skin structure infections (absssi) in adult and pediatric patients using a two-dose regimen of dalbavancin

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

DALVANCE family patents

Family Patents

41. Daurismo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431597 PFIZER Benzimidazole derivatives
Jun, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-224) Nov 21, 2025
New Chemical Entity Exclusivity(NCE) Nov 21, 2023

Drugs and Companies using GLASDEGIB MALEATE ingredient

NCE-1 date: 21 November, 2022

Market Authorisation Date: 21 November, 2018

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

DAURISMO family patents

Family Patents

42. Dexilant patents expiration

DEXILANT's oppositions filed in EPO
Can you believe DEXILANT received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8871273 TAKEDA PHARMS USA Method for producing granules
Jan, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 30, 2012
New Patient Population(NPP) Jul 08, 2019
Pediatric Exclusivity(PED) Jul 30, 2012

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of DEXILANT before it's drug patent expiration?
More Information on Dosage

DEXILANT family patents

Family Patents

43. Dexilant Solutab patents expiration

DEXILANT SOLUTAB's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8871273 TAKEDA PHARMS USA Method for producing granules
Jan, 2028

(3 years from now)

US8871273

(Pediatric)

TAKEDA PHARMS USA Method for producing granules
Jul, 2028

(4 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 26 January, 2016

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage

DEXILANT SOLUTAB family patents

Family Patents

44. Differin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7998467 GALDERMA LABS LP Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers
May, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Mar 17, 2013

Drugs and Companies using ADAPALENE ingredient

Market Authorisation Date: 17 March, 2010

Treatment: Treatment of acne

Dosage: LOTION;TOPICAL

How can I launch a generic of DIFFERIN before it's drug patent expiration?
More Information on Dosage

DIFFERIN family patents

Family Patents

45. Dificid patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859510

(Pediatric)

CUBIST PHARMS LLC Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jan, 2028

(3 years from now)

US7378508

(Pediatric)

CUBIST PHARMS LLC Polymorphic crystalline forms of tiacumicin B
Jan, 2028

(3 years from now)

US7863249

(Pediatric)

CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jan, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-367) Jan 24, 2027
Pediatric Exclusivity(PED) Jul 24, 2023
New Product(NP) Jan 24, 2023

Drugs and Companies using FIDAXOMICIN ingredient

Market Authorisation Date: 24 January, 2020

Treatment: NA

Dosage: FOR SUSPENSION;ORAL; TABLET;ORAL

How can I launch a generic of DIFICID before it's drug patent expiration?
More Information on Dosage

DIFICID family patents

Family Patents

46. Doral patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7608616 GALT PHARMS Methods for reducing the risk of an adverse drug interaction in a patient suffering from insomnia
Jun, 2028

(4 years from now)

Drugs and Companies using QUAZEPAM ingredient

Market Authorisation Date: 26 February, 1987

Treatment: Method for treating insomnia while reducing the risk of an adverse drug interaction

Dosage: TABLET;ORAL

More Information on Dosage

DORAL family patents

Family Patents

47. Doryx patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8715724 MAYNE PHARMA Tabletting process
Feb, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) Apr 11, 2016
New Dosing Schedule(D-136) Apr 11, 2016

Drugs and Companies using DOXYCYCLINE HYCLATE ingredient

Market Authorisation Date: 19 December, 2014

Treatment: NA

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of DORYX before it's drug patent expiration?
More Information on Dosage

DORYX family patents

Family Patents

48. Doryx Mpc patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8715724 MAYNE PHARMA Tabletting process
Feb, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) Apr 11, 2016
New Dosing Schedule(D-136) Apr 11, 2016

Drugs and Companies using DOXYCYCLINE HYCLATE ingredient

Market Authorisation Date: 19 December, 2014

Treatment: NA

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of DORYX MPC before it's drug patent expiration?
More Information on Dosage

DORYX MPC family patents

Family Patents

49. Dovato patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8129385

(Pediatric)

VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Apr, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Apr 08, 2022
New Indication(I-839) Aug 06, 2023

Drugs and Companies using DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

Market Authorisation Date: 08 April, 2019

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of DOVATO before it's drug patent expiration?
More Information on Dosage

DOVATO family patents

Family Patents

50. Duetact patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071130 TAKEDA PHARMS USA Solid preparation
Jun, 2028

(4 years from now)

Drugs and Companies using GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 July, 2006

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of DUETACT before it's drug patent expiration?
More Information on Dosage

DUETACT family patents

Family Patents

51. Duzallo patents expiration

Can you believe DUZALLO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8283369 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Nov, 2028

(4 years from now)

US10183012 IRONWOOD PHARMS INC Compounds and compositions and methods of use
Nov, 2028

(4 years from now)

Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Market Authorisation Date: 18 August, 2017

Treatment: Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone

Dosage: TABLET;ORAL

More Information on Dosage

DUZALLO family patents

Family Patents

52. Edarbi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066936 AZURITY Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
Mar, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 25, 2016

Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient

NCE-1 date: 25 February, 2015

Market Authorisation Date: 25 February, 2011

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of EDARBI before it's drug patent expiration?
More Information on Dosage

EDARBI family patents

Family Patents

53. Edarbyclor patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066936 AZURITY Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
Mar, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Dec 20, 2014
New Chemical Entity Exclusivity(NCE) Feb 25, 2016

Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient

NCE-1 date: 25 February, 2015

Market Authorisation Date: 20 December, 2011

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of EDARBYCLOR before it's drug patent expiration?
More Information on Dosage

EDARBYCLOR family patents

Family Patents

54. Ella patents expiration

ELLA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9844510 LAB HRA PHARMA Ulipristal acetate tablets
Dec, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-271) Jun 24, 2024
New Chemical Entity Exclusivity(NCE) Aug 13, 2015

Drugs and Companies using ULIPRISTAL ACETATE ingredient

NCE-1 date: 13 August, 2014

Market Authorisation Date: 13 August, 2010

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ELLA before it's drug patent expiration?
More Information on Dosage

ELLA family patents

Family Patents

55. Elucirem patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8114863 GUERBET Compounds comprising short aminoalcohol chains and metal complexes for medical imaging
Sep, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 21, 2027

Drugs and Companies using GADOPICLENOL ingredient

NCE-1 date: 21 September, 2026

Market Authorisation Date: 21 September, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ELUCIREM family patents

Family Patents

56. Envarsus Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10166190 VELOXIS PHARMS INC Stabilized tacrolimus composition
May, 2028

(4 years from now)

US10864199 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients
May, 2028

(4 years from now)

US9549918 VELOXIS PHARMS INC Stabilized tacrolimus composition
May, 2028

(4 years from now)

US11419823 VELOXIS PHARMS INC Stabilized tacrolimus composition
May, 2028

(4 years from now)

US11110081 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients
May, 2028

(4 years from now)

US11123331 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients
May, 2028

(4 years from now)

US8664239 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients
Aug, 2028

(4 years from now)

US8685998 VELOXIS PHARMS INC Tacrolimus for improved treatment of transplant patients
Aug, 2028

(4 years from now)

US8644239 VELOXIS PHARMS INC Method and apparatus for allocating and processing sequences in communication system
Aug, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Jul 10, 2022
Orphan Drug Exclusivity(ODE-94) Jul 10, 2022

Drugs and Companies using TACROLIMUS ingredient

Market Authorisation Date: 10 July, 2015

Treatment: Prophylaxis of organ rejection in de novo transplant patient; Prophylaxis of organ rejection in patients converted from tacrolimus immediate-release formulations

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ENVARSUS XR before it's drug patent expiration?
More Information on Dosage

ENVARSUS XR family patents

Family Patents

57. Epclusa patents expiration

EPCLUSA's oppositions filed in EPO
EPCLUSA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(3 years from now)

US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(3 years from now)

US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735372 GILEAD SCIENCES INC NA
Mar, 2028

(3 years from now)

US8580765

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(4 years from now)

US8334270

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(4 years from now)

US9085573

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(4 years from now)

US8735372

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-293) Mar 19, 2027
M(M-264) Jul 14, 2023
Orphan Drug Exclusivity(ODE-376) Jun 10, 2028
M(M-277) Apr 27, 2025
Pediatric Exclusivity(PED) Dec 10, 2028
New Dosing Schedule(D-177) Nov 15, 2022
New Patient Population(NPP) Mar 19, 2023
New Chemical Entity Exclusivity(NCE) Jun 28, 2021
New Strength(NS) Mar 19, 2023

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

NCE-1 date: 11 December, 2027

Market Authorisation Date: 19 March, 2020

Treatment: For the treatment of hepatitis c

Dosage: TABLET;ORAL; PELLETS;ORAL

More Information on Dosage

EPCLUSA family patents

Family Patents

58. Epsolay patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9868103 GALDERMA LABS LP Metal oxide coating of water insoluble ingredients
Aug, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 22, 2025

Drugs and Companies using BENZOYL PEROXIDE ingredient

Market Authorisation Date: 22 April, 2022

Treatment: Topical treatment of inflammatory lesions of rosacea in adults 18 years of age and older

Dosage: CREAM;TOPICAL

More Information on Dosage

EPSOLAY family patents

Family Patents

59. Erivedge patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7888364 GENENTECH Pyridyl inhibitors of hedgehog signalling
Nov, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278961 GENENTECH Pyridyl inhibitors of hedgehog signalling
Dec, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 30, 2017

Drugs and Companies using VISMODEGIB ingredient

NCE-1 date: 31 January, 2016

Market Authorisation Date: 30 January, 2012

Treatment: Method of using vismodegib to treat cancer in a mammal

Dosage: CAPSULE;ORAL

More Information on Dosage

ERIVEDGE family patents

Family Patents

60. Esbriet patents expiration

ESBRIET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8383150 GENENTECH INC Granulate formulation of pirfenidone and pharmaceutically acceptable excipients
May, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-77) Oct 15, 2021
New Chemical Entity Exclusivity(NCE) Oct 15, 2019
Orphan Drug Exclusivity(ODE) Oct 15, 2021

Drugs and Companies using PIRFENIDONE ingredient

NCE-1 date: 15 October, 2018

Market Authorisation Date: 11 January, 2017

Treatment: Method of administering a granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone as recited in claim 1, to treat idiopathic pulmonary fibrosis

Dosage: TABLET;ORAL

How can I launch a generic of ESBRIET before it's drug patent expiration?
More Information on Dosage

ESBRIET family patents

Family Patents

61. Evzio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947017 KALEO INC Devices, systems and methods for medicament delivery
Mar, 2028

(3 years from now)

US7749194 KALEO INC Devices, systems, and methods for medicament delivery
Oct, 2028

(4 years from now)

US8231573 KALEO INC Medicament delivery device having an electronic circuit system
Nov, 2028

(4 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO family patents

Family Patents

62. Evzio (autoinjector) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7947017 KALEO INC Devices, systems and methods for medicament delivery
Mar, 2028

(3 years from now)

US7749194 KALEO INC Devices, systems, and methods for medicament delivery
Oct, 2028

(4 years from now)

US8231573 KALEO INC Medicament delivery device having an electronic circuit system
Nov, 2028

(4 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO (AUTOINJECTOR) family patents

Family Patents

63. Exondys 51 patents expiration

EXONDYS 51's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9243245 SAREPTA THERAPS INC Means and methods for counteracting muscle disorders
Oct, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48468 SAREPTA THERAPS INC Means and methods for counteracting muscle disorders
Oct, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Sep 19, 2023
New Chemical Entity Exclusivity(NCE) Sep 19, 2021
Orphan Drug Exclusivity(ODE-122) Sep 19, 2023

Drugs and Companies using ETEPLIRSEN ingredient

NCE-1 date: 19 September, 2020

Market Authorisation Date: 19 September, 2016

Treatment: Treatment of dmd in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Increasing production of functional dystrophin protein in dmd patients having a mutation of the dmd...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

EXONDYS 51 family patents

Family Patents

64. Farxiga patents expiration

FARXIGA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8221786 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US7851502 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Aug, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-857) Apr 30, 2024
M(M-298) May 08, 2026
M(M-238) Feb 22, 2022
New Indication(I-834) May 05, 2023
M(M-212) Oct 20, 2020
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-157) Mar 11, 2018
New Indication(I-841) Oct 18, 2022

Drugs and Companies using DAPAGLIFLOZIN ingredient

NCE-1 date: 08 January, 2018

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET;ORAL

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

65. Farydak patents expiration

FARYDAK's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7989494 SECURA Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
Jan, 2028

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8883842 SECURA Use of HDAC inhibitors for the treatment of myeloma
Jun, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 23, 2020
Orphan Drug Exclusivity(ODE) Feb 23, 2022
Orphan Drug Exclusivity(ODE-89) Feb 23, 2022

Drugs and Companies using PANOBINOSTAT LACTATE ingredient

NCE-1 date: 23 February, 2019

Market Authorisation Date: 23 February, 2015

Treatment: Treatment of multiple myeloma, in combination with bortezomib and dexamethasone

Dosage: CAPSULE;ORAL

More Information on Dosage

FARYDAK family patents

Family Patents

66. Fentora patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7862833 CEPHALON Effervescent oral opiate dosage forms and methods of administering opiates
Jun, 2028

(4 years from now)

US7862832 CEPHALON Generally linear effervescent oral fentanyl dosage form and methods of administering
Jun, 2028

(4 years from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 25 September, 2006

Treatment: NA

Dosage: TABLET;BUCCAL, SUBLINGUAL

How can I launch a generic of FENTORA before it's drug patent expiration?
More Information on Dosage

FENTORA family patents

Family Patents

67. Flo-pred patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7799331 TARO Oral suspension of prednisolone acetate
Oct, 2028

(4 years from now)

Drugs and Companies using PREDNISOLONE ACETATE ingredient

Market Authorisation Date: 17 January, 2008

Treatment: Treatment of allergic reactions

Dosage: SUSPENSION;ORAL

More Information on Dosage

FLO-PRED family patents

Family Patents

68. Flonase Sensimist Allergy Relief patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8347879 GLAXOSMITHKLINE CONS Fluid dispensing device
Jul, 2028

(4 years from now)

US8147461 GLAXOSMITHKLINE CONS Fluid dispensing device
Oct, 2028

(4 years from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 27 April, 2007

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

FLONASE SENSIMIST ALLERGY RELIEF family patents

Family Patents

69. Fruzaqla patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7829574 TAKEDA PHARMS USA Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
May, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8212033 TAKEDA PHARMS USA Use of substituted quinazoline compounds in treating angiogenesis-related diseases
May, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 30, 2028

Drugs and Companies using FRUQUINTINIB ingredient

NCE-1 date: 01 December, 2027

Market Authorisation Date: 08 November, 2023

Treatment: Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-vegf therapy, and, if ras wild-ty...

Dosage: CAPSULE;ORAL

More Information on Dosage

FRUZAQLA family patents

Family Patents

70. Galafold patents expiration

Can you believe GALAFOLD received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10925866 AMICUS THERAP US Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
Apr, 2028

(4 years from now)

US9999618 AMICUS THERAP US Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
Apr, 2028

(4 years from now)

US10525045 AMICUS THERAP US Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
Apr, 2028

(4 years from now)

US11033538 AMICUS THERAP US Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
Apr, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-205) Aug 10, 2025
New Chemical Entity Exclusivity(NCE) Aug 10, 2023

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

NCE-1 date: 10 August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: The treatment of fabry patients; A method of reducing left ventricular mass index (lvmi) in a fabry patient by administering migalastat

Dosage: CAPSULE;ORAL

How can I launch a generic of GALAFOLD before it's drug patent expiration?
More Information on Dosage

GALAFOLD family patents

Family Patents

71. Givlaari patents expiration

Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(4 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2024
Orphan Drug Exclusivity(ODE-273) Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: 21 November, 2023

Market Authorisation Date: 20 November, 2019

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

GIVLAARI family patents

Family Patents

72. Glyxambi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-739) Dec 02, 2019
New Combination(NC) Jan 30, 2018
M(M-258) Jul 03, 2022
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
M(M-252) Mar 30, 2023

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

NCE-1 date: 01 August, 2018

Market Authorisation Date: 30 January, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of GLYXAMBI before it's drug patent expiration?
More Information on Dosage

GLYXAMBI family patents

Family Patents

73. Gocovri patents expiration

Can you believe GOCOVRI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8389578 ADAMAS OPERATIONS Composition and method for treating neurological disease
Jan, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-153) Aug 24, 2024
Orphan Drug Exclusivity(ODE) Aug 24, 2024
New Indication(I-769) Aug 24, 2020
New Product(NP) Aug 24, 2020

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 August, 2017

Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving immediate release levodopa-based therapy, with or without concomitant dopaminergic medications

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of GOCOVRI before it's drug patent expiration?
More Information on Dosage

GOCOVRI family patents

Family Patents

74. Harvoni patents expiration

HARVONI's oppositions filed in EPO
HARVONI Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(3 years from now)

US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(3 years from now)

US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735372 GILEAD SCIENCES INC NA
Mar, 2028

(3 years from now)

US9085573

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(4 years from now)

US8735372

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(4 years from now)

US8334270

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(4 years from now)

US8580765

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-136) Apr 07, 2024
ODE*(ODE*) Apr 07, 2024
Pediatric Exclusivity(PED) Oct 07, 2024
Orphan Drug Exclusivity(ODE) Apr 07, 2024
New Chemical Entity Exclusivity(NCE) Oct 10, 2019
New Dosing Schedule(D-158) Feb 12, 2019
New Dosing Schedule(D-159) Feb 12, 2019
New Dosing Schedule(D-160) Feb 12, 2019
New Patient Population(NPP) Apr 07, 2020
New Indication(I-718) Nov 12, 2018
New Dosing Schedule(D-153) Nov 12, 2018
New Indication(I-719) Nov 12, 2018
New Indication(I-720) Nov 12, 2018
New Dosing Schedule(D-177) Nov 15, 2022

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

NCE-1 date: 08 October, 2023

Market Authorisation Date: 28 August, 2019

Treatment: For the treatment of hepatitis c

Dosage: TABLET;ORAL; PELLETS;ORAL

More Information on Dosage

HARVONI family patents

Family Patents

75. Hemangeol patents expiration

HEMANGEOL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8987262 PIERRE FABRE DERMA Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Oct, 2028

(4 years from now)

US8338489 PIERRE FABRE DERMA Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Oct, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Mar 14, 2021
New Product(NP) Mar 14, 2017
Orphan Drug Exclusivity(ODE-62) Mar 14, 2021

Drugs and Companies using PROPRANOLOL HYDROCHLORIDE ingredient

Market Authorisation Date: 14 March, 2014

Treatment: Method to treat infantile hemangioma; Method to treat hemangioma.

Dosage: SOLUTION;ORAL

How can I launch a generic of HEMANGEOL before it's drug patent expiration?
More Information on Dosage

HEMANGEOL family patents

Family Patents

76. Imbruvica patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8008309

(Pediatric)

PHARMACYCLICS LLC Inhibitors of bruton's tyrosine kinase
May, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-405) Aug 24, 2029
ODE*(ODE*) Aug 02, 2024
New Patient Population(NPP) Aug 24, 2025
Pediatric Exclusivity(PED) Feb 24, 2026
M(M-236) Jan 25, 2022
New Dosing Schedule(D-176) Aug 24, 2021
New Chemical Entity Exclusivity(NCE) Nov 13, 2018

Drugs and Companies using IBRUTINIB ingredient

NCE-1 date: 24 February, 2025

Market Authorisation Date: 16 February, 2018

Treatment: NA

Dosage: CAPSULE;ORAL; TABLET;ORAL; SUSPENSION;ORAL

How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage

IMBRUVICA family patents

Family Patents

77. Incivek patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431615 VERTEX PHARMS Dose forms
May, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 23, 2016

Drugs and Companies using TELAPREVIR ingredient

NCE-1 date: 24 May, 2015

Market Authorisation Date: 23 May, 2011

Treatment: Method of treating chronic hepatitis c

Dosage: TABLET;ORAL

More Information on Dosage

INCIVEK family patents

Family Patents

78. Incruse Ellipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8161968 GLAXO GRP ENGLAND Medicament dispenser
Feb, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 18, 2018
M(M-172) Feb 24, 2019
M(M-245) Jun 09, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE ingredient

NCE-1 date: 18 December, 2017

Market Authorisation Date: 30 April, 2014

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

INCRUSE ELLIPTA family patents

Family Patents

79. Injectafer patents expiration

INJECTAFER's oppositions filed in EPO
INJECTAFER Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7754702 AM REGENT Methods and compositions for administration of iron
Feb, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-915) May 31, 2026
New Patient Population(NPP) Nov 19, 2024
New Strength(NS) Apr 28, 2024
New Product(NP) Jul 25, 2016

Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient

Market Authorisation Date: 28 April, 2021

Treatment: Method to treat ida in adults & pediatric patients 1 yr & older with intolerance or unsatisfactory response to oral iron & weighing at least 40 kg by intravenously administering ferric carboxymaltose ...

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of INJECTAFER before it's drug patent expiration?
More Information on Dosage

INJECTAFER family patents

Family Patents

80. Inpefa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7781577 LEXICON PHARMS INC Inhibitors of sodium glucose co-transporter 2 and methods of their use
May, 2028

(4 years from now)

US8476413 LEXICON PHARMS INC Sulfanyl-tetrahydropyran-based compounds and methods of their use
May, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 26, 2028

Drugs and Companies using SOTAGLIFLOZIN ingredient

NCE-1 date: 27 May, 2027

Market Authorisation Date: 26 May, 2023

Treatment: Reduction of risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardi...

Dosage: TABLET;ORAL

More Information on Dosage

INPEFA family patents

Family Patents

81. Inqovi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9567363 OTSUKA Certain compounds, compositions and methods
Oct, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618075 OTSUKA Certain compounds, compositions and methods
Oct, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 07, 2025
Orphan Drug Exclusivity(ODE-316) Jul 07, 2027

Drugs and Companies using CEDAZURIDINE; DECITABINE ingredient

NCE-1 date: 07 July, 2024

Market Authorisation Date: 07 July, 2020

Treatment: Method for inhibiting degradation of a cda substrate by administering cedazuridine

Dosage: TABLET;ORAL

More Information on Dosage

INQOVI family patents

Family Patents

82. Inrebic patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8138199 IMPACT Use of bi-aryl meta-pyrimidine inhibitors of kinases
Jun, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-259) Aug 16, 2026
New Chemical Entity Exclusivity(NCE) Aug 16, 2024

Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient

NCE-1 date: 17 August, 2023

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis

Dosage: CAPSULE;ORAL

More Information on Dosage

INREBIC family patents

Family Patents

83. Intrarosa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629129 MILLICENT Pharmaceutical compositions
Aug, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 16, 2021

Drugs and Companies using PRASTERONE ingredient

NCE-1 date: 16 November, 2020

Market Authorisation Date: 16 November, 2016

Treatment: NA

Dosage: INSERT;VAGINAL

More Information on Dosage

INTRAROSA family patents

Family Patents

84. Isentress patents expiration

ISENTRESS's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8852632 MSD SUB MERCK Pharmaceutical formulation containing a release rate controlling composition
Jan, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) May 26, 2020
New Dosing Schedule(D-167) May 26, 2020
New Patient Population(NPP) Dec 21, 2014
Pediatric Exclusivity(PED) May 22, 2021
M(M-114) Mar 28, 2015
New Chemical Entity Exclusivity(NCE) Oct 12, 2012

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

NCE-1 date: 22 May, 2020

Market Authorisation Date: 12 October, 2007

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of ISENTRESS before it's drug patent expiration?
More Information on Dosage

ISENTRESS family patents

Family Patents